We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
LGC Clinical Diagnostics

TECAN GROUP LTD.

Tecan is a provider of automated laboratory instruments and solutions for people working in clinical diagnostics, bas... read more Featured Products: More products

Download Mobile App




Blood Test May Help Identify Fetal Alcohol Spectrum Disorders

By LabMedica International staff writers
Posted on 25 Nov 2016
Fetal alcohol syndrome is a severe form of a spectrum of mental and physical disabilities called fetal alcohol spectrum disorders (FASD) that can affect children's development with long-lasting consequences and a blood test has been developed to predict the severity of disability.

Children and adults affected by FASD may experience a range of symptoms, from physical changes like a small head and subtle differences in facial characteristics to learning difficulties and behavioral issues. More...
In the In the USA and Western Europe, it is estimated that 2% to 5% of school-age children are affected by FASD and in some parts of the world, the number is higher.

A team of collaborating scientists co-led by those at University of California San Diego (La Jolla, CA, USA) looked at birth outcomes for 68 pregnant women enrolled in the study at two perinatal care clinics in western Ukraine. They selected a sample consisting of three groups. The first group of 22 represented moderate to heavily-exposed mothers with an FASD affected child (HEa); the second group of 23 represented moderate to heavily-exposed mothers with an apparently unaffected child, i.e., no facial features, normal head circumference and normal neurobehavioral test scores (HEua); and 23 low alcohol consuming or unexposed mothers with an unaffected child (UE).

Plasma sample quality control analysis and RNA isolation was performed and micro ribonucleic acid (miRNA) profiles were measured using Human miRCURY LNA microRNA real-time polymerase chain reaction (PCR) arrays (Exiqon, Vedbæk, Denmark), which assess 752 unique miRNAs. This platform has been shown in comparison tests, to detect miRNAs in biofluids with greater sensitivity and specificity than other miRNA detection methods. Human Placental Lactogen (hPL) concentration in human plasma was quantitatively determined using a commercially available solid phase sandwich-type enzyme-linked immunoassay (hPL micro-ELISA, Leinco Technologies, Inc, St. Louis, MO, USA). The chromogenic reaction product was quantified spectrometrically using an Infinite m200 at 450nm (Tecan, Männedorf, Switzerland).

The results of the study indicated that moderate to high levels of alcohol exposure during early pregnancy resulted in significant differences in some circulating small RNA molecules called miRNAs in maternal blood. These differences were particularly notable in mothers whose infants showed some physical or neurobehavioral signs of alcohol effects in the first 12 months of life. Plasma placental lactogen content in late pregnancy was not significantly different among HEa, HEua and UE groups.

Christina Chambers, PhD, a professor of pediatrics and co-senior author of the study said, “Although it is generally true that binge-drinking during pregnancy presents the greatest risk, not all women who consume substantial amounts of alcohol in pregnancy will have a child who is clearly affected. That's why we examined specific biomarkers in the mother's blood in the second and third trimester of her pregnancy to determine if they are useful in identifying children who could benefit from early interventions.” The study was published on November 9, 2016, in the journal Public Library of Science ONE.

Related Links:
University of California San Diego
Exiqon
Leinco Technologies
Tecan

Gold Member
Troponin T QC
Troponin T Quality Control
Serological Pipet Controller
PIPETBOY GENIUS
New
Integrated Biochemical & Immunological System
Biolumi CX8
New
Drug Test Kit
DrugCheck 3000
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








DIASOURCE (A Biovendor Company)

Channels

Hematology

view channel
Image: CitoCBC is the world first cartridge-based CBC to be granted CLIA Waived status by FDA (Photo courtesy of CytoChip)

Disposable Cartridge-Based Test Delivers Rapid and Accurate CBC Results

Complete Blood Count (CBC) is one of the most commonly ordered lab tests, crucial for diagnosing diseases, monitoring therapies, and conducting routine health screenings. However, more than 90% of physician... Read more

Immunology

view channel
Image: A simple blood test could replace surgical biopsies for early detecion of heart transplant rejection (Photo courtesy of Shutterstock)

Blood Test Detects Organ Rejection in Heart Transplant Patients

Following a heart transplant, patients are required to undergo surgical biopsies so that physicians can assess the possibility of organ rejection. Rejection happens when the recipient’s immune system identifies... Read more

Pathology

view channel
These images illustrate how precision oncology Organ Chips recapitulate individual patients’ responses to chemotherapy (Photo courtesy of Wyss Institute at Harvard University)

Cancer Chip Accurately Predicts Patient-Specific Chemotherapy Response

Esophageal adenocarcinoma (EAC), one of the two primary types of esophageal cancer, ranks as the sixth leading cause of cancer-related deaths worldwide and currently lacks effective targeted therapies.... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.